Skip to content
Gusperimus
Gusperimus is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L04: Immunosuppressants
L04A: Immunosuppressants
L04AA: Selective immunosuppressants
L04AA19: Gusperimus
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Granulomatosis with polyangiitisD014890EFO_0005297M31.3112
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E1011
Lupus nephritisD008181EFO_0005761111
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGUSPERIMUS
INNgusperimus
Description
Gusperimus is a N-acyl-amino acid.
Classification
Small molecule
Drug classimmunosuppressives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
N=C(N)NCCCCCCC(=O)NC(O)C(=O)NCCCCNCCCN
Identifiers
PDB
CAS-ID98629-43-7
RxCUI
ChEMBL IDCHEMBL406117
ChEBI ID
PubChem CID55362
DrugBankDB12692
UNII IDUJ0ZJ76DO9 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 72 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details